NysnoBio

09/13/2022

Congratulations to Professor Nobutaka Hattori, member of NysnoBio's esteemed Scientific Advisory Board, on your award for Outstanding Scholar and Role-Model Clinician in the Field! Professor Hattori will be recognized by the International Parkinson and Movement Disorder Society this Friday at the Presidential Lectures in Madrid.
https://www.nysnobio.com/ | https://www.mdscongress.org/Program/Events/Presidential-Lectures

09/06/2022

Exciting advances in YOPD research! NysnoBio CEO Jennifer Johnston, PhD, discusses challenges and options that are specific to Young Onset Parkinson's disease patients at this YOPN virtual event. REGISTER NOW. https://yopnetwork.org/event-4899852

06/01/2022

New Insight! 💡 NysnoBio SAB member Professor Nobutaka Hattori has published new insight into Parkin activation, and NysnoBio is advancing a potential biomarker based on this work.
nysnobio.com

Mutations in the genes encoding Parkin/PRKN and PTEN-induced kinase 1 (PINK1) cause selective degeneration of the midbrain dopaminergic neurons in autosomal recessive juvenile parkinsonism (1,2).

05/05/2022

https://www.nysnobio.com/news/nysnobio-awarded-mjff-grant-for-first-clinical-study

NysnoBio announces funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the study Neural Network Imaging Analysis in Parkin-PD Patients. Drs. Jennifer Johnston (Nysnobio), David Eidelberg, and Genko Oyama, will combine their talents and expertise on this new

04/26/2022

Our busy CEO, Dr. Jennifer Johnston, is doing double duty at the 2nd Annual Ligase Targeting Drug Development virtual summit this week! Today she'll be talking small molecules and protein degraders, and tomorrow she leads a roundtable session about today's challenges in the field. Go JJ! 💪
nysnobio.com
ligase-drugdevelopment.com/speaker/jennifer-johnston/
The Ligase Targeting Drug Development summit is an unrivaled forum that unites leading bio industry giants and key academics, enabling them to share unseen data and collaborative efforts, and to discuss the next steps to successfully select, validate and translate E3s into a viable therapy.

04/12/2022

NysnoBio's at the CHI Gene Therapy Summit in Boston this week! Don't miss Keynote Speaker Dr. Jennifer Johnston, Cofounder and CEO of NysnoBio, as she discusses how we can use human genetic data to define clinical populations for new therapies. nysnobio.com
https://www.healthtech.com/gene-therapies/advancing-gene-therapy

03/01/2022

We've found the missing piece: NysnoBio welcomes Dr. Leonard Post to our SAB! Dr. Post brings insights to NysnoBio from his pioneering work advancing multiple gene therapy programs through the clinic, as well as expertise from launching multiple successful biotech companies. The addition of Dr. Post is a key element as we advance our genetic medicines towards defined patient populations in desperate need of novel therapies. Proud to welcome you, Len! https://www.nysnobio.com/about

02/08/2022

Looking forward to our Parkin Summit meeting on Feb 10th! NysnoBio and several of the world’s top Parkinson’s Disease clinicians, with specific expertise in Parkin-linked PD, will put our heads together to advance the cause: We're actively building a Parkin-specific patient profile as we move toward Phase 1 trials in this group of early-onset, genetically linked PD patients. PROGRESS! 💪 nysnobio.com

12/16/2021

NysnoBio's at Pacifichem 2021! A fully-virtual Congress this year, don't miss Jennifer Johnston, PhD, Cofounder and CEO of NysnoBio, on Fri at 10:35 PST as she discusses small molecule activation of Parkin E3 ubiquitin ligase.
nysnobio.com

12/08/2021

NysnoBio's ground-breaking work is going on display: We've been selected as a semi-finalist for the annual BioPitch competition at the BioFlorida conference in Orlando! Every year, the most innovative seed and early-stage life science companies get this promising opportunity to pitch to life science investors. Tomorrow our CEO, Jennifer Johnston, is one of just 16 presenters who will vie for a spot in Friday's finals. Go, JJ! 💪
https://www.bioflorida.com/page/2021BioPitch
https://www.nysnobio.com/

10/05/2021

In a webinar brought to you by Bio-Techne and The Scientist, Dr. Jennifer Johnston discusses the past 20 years of her career, and how her basic research into ubiquitin-proteasome system elements—including Parkin E3 ligase—continues to provide the insight needed to move gene therapy and small molecule therapeutics toward the clinic. Watch it here!

In a webinar brought to you by Bio-Techne and The Scientist, Dr. Jennifer Johnston discusses the past 20 years of her career, and how her basic research into ubiquitin-proteasome system elements—including Parkin E3 ligase—continues to

08/03/2021

Washington Post Health: Professor J. William Langston, NysnoBio Scientific Advisory Board (SAB) Member, discusses susceptibility to Parkinson's disease.

Some experts are calling for a long-term study that would follow generations of people to learn more about this progressive disorder of the nervous system.